Introduction {#H1-1-ZOI180057}
============

The health care costs of overweight, obesity, and type 2 diabetes are increasing,^[@zoi180057r1]^ and conventional weight-loss diets with daily energy restriction are difficult to adhere to in the long term.^[@zoi180057r2]^ Intermittent energy restriction, short periods of severe energy restriction followed by longer periods of habitual eating, has been suggested as a potential strategy because it offers a reduced burden of dietary restriction and may therefore be more acceptable.^[@zoi180057r3]^ In animal studies, intermittent energy restriction appears to be equally effective as, if not more effective than, continuous energy restriction for the reduction of disease risk factors.^[@zoi180057r4]^ Studies in the healthy overweight and obese population have determined that intermittent energy restriction is an effective method for achieving weight loss comparable to that achieved by continuous energy restriction, with weight loss of 3 to 5 kg after approximately 10 weeks.^[@zoi180057r5]^ Other methods of intermittent energy restriction, such as alternate-day modified fasting, have also demonstrated similar weight loss compared with that achieved by continuous energy restriction.^[@zoi180057r6]^ For individuals with type 2 diabetes, investigators have evaluated the effects of intermittent very-low-calorie diets used within a continuous energy restriction diet compared with continuous energy restriction alone,^[@zoi180057r7],[@zoi180057r8],[@zoi180057r9]^ but they have not compared intermittent dieting with continuous dieting. We previously published a pilot trial that demonstrated that a 2-day intermittent energy restriction diet provides an effective alternative method for both glycemic control and weight loss compared with a continuous energy restriction diet over a 3-month period.^[@zoi180057r10]^ The objective of this randomized noninferiority trial was to ascertain the long-term effects of a 2-day intermittent energy restriction diet compared with continuous energy restriction during a 12-month period for patients with type 2 diabetes. We hypothesized that equal improvements to hemoglobin A~1c~ (HbA~1c~) level and weight would occur, as seen in our 3-month pilot trial, thus offering a successful alternative treatment strategy for use in clinical practice.

Methods {#H1-2-ZOI180057}
=======

Study Design {#H2-1-ZOI180057}
------------

This was a parallel randomized clinical trial, conducted at the Sansom Institute of Health Research, University of South Australia, from April 7, 2015, to September 7, 2017. Reporting in this article is aligned with Consolidated Standards of Reporting Trials ([CONSORT](http://www.equator-network.org/reporting-guidelines/consort/)) guideline standards, and the full procedure can be found in [Supplement 1](#note-ZOI180057-1-s){ref-type="supplementary-material"}. Ethics approval was obtained from the University of South Australia Human Research Ethics Committee. Procedures were in accordance with ethical standards, including obtaining written informed consent.

Participants and Randomization {#H2-2-ZOI180057}
------------------------------

Participants were recruited using flyers posted in public places and via advertisements in print and broadcast media. Inclusion criteria were adults (≥18 years of age) with type 2 diabetes who were overweight or obese (body mass index ≥27 \[calculated as weight in kilograms divided by height in meters squared\]) and not pregnant or breastfeeding. Participants reported being otherwise healthy with blood pressure of less than 160/100 mm Hg and no previous weight loss surgery. There was no difference in inclusion criteria between this trial and the pilot trial.^[@zoi180057r10]^ Of the 195 individuals screened for eligibility, 137 were randomized 1:1 to treatment groups, stratified by sex and body mass index (as obese or nonobese), at the initial clinic visit. Randomization was completed using an online-generated random number allocation sequence and was not blinded; participants were allocated to groups by the study dietitian according to the randomization schedule. Participants received an A\$25 (US \$19) voucher at 3 and 12 months to thank them for their participation; participants were not aware that they would receive a voucher.

Interventions {#H2-3-ZOI180057}
-------------

Participants randomized to the intermittent energy restriction group followed a diet of 500 to 600 kcal/d for 2 days of the week and followed their usual diet for the other 5 days. The intermittent diet days were mostly nonconsecutive, with a minimum of 50 g of protein per day, in accordance with the very-low-calorie diet guidelines.^[@zoi180057r11]^ See eTable 1 in [Supplement 2](#note-ZOI180057-1-s){ref-type="supplementary-material"} for an example meal plan. The continuous energy restriction group followed a diet of 1200 to 1500 kcal/d (30% protein, 45% carbohydrate, and 25% fat).^[@zoi180057r12]^ The total weekly energy estimate was based on the mean adult intake of approximately 2100 kcal/d.^[@zoi180057r13]^ A 75% energy restriction 2 days per week with 5 habitual eating days per week is approximately 11 500 kcal/wk and a 30% daily energy restriction is approximately 10 300 kcal/wk; therefore, both groups had similar dietary energy restrictions recommended. Both groups received written dietary information booklets with portion advice and sample menus; no food or meal replacements were provided. Participants were given digital kitchen scales and encouraged to weigh foods to ensure accuracy of intake. Appointments were with a dietitian (S.C.) and occurred every 2 weeks for the first 3 months and every 2 to 3 months for the final 9 months. Blood glucose control, weight, and diet checklists were reviewed at each visit to assess dietary compliance. The interventions assessed in this trial were no different from the interventions in the pilot trial.^[@zoi180057r10]^

Medication Management {#H2-4-ZOI180057}
---------------------

The medication management protocol was developed after reviewing the literature^[@zoi180057r14]^ and consulting with an endocrinologist (P.M.C.). Management occurred in conjunction with the participant, the study dietitian, and the endocrinologist, as well as with the participant's medical practitioner. The protocol for a change in medication varied slightly throughout the trial. The initial medication protocol can be found in eTable 2 in [Supplement 2](#note-ZOI180057-1-s){ref-type="supplementary-material"} and was modified, primarily owing to hypoglycemia, after the 38th participant commenced the trial. The new protocol required the discontinuation of sulfonylureas and insulin for all participants if the baseline HbA~1c~ level was less than 7% (to convert to proportion of total hemoglobin, multiply by 0.01). If the HbA~1c~ level was higher than 7% but less than 10%, then sulfonylureas and insulin were discontinued on intermittent energy restriction days only, and long-acting insulin was discontinued the night before an intermittent energy restriction day. Medications could be reduced in the continuous energy restriction diet group depending on dose, at the endocrinologist's discretion. If the HbA~1c~ level was higher than 10%, sulfonylurea medications remained unchanged, but long-acting insulin was decreased by approximately 10 units on intermittent energy restriction diet days only. Although most participants followed the protocol, the endocrinologist worked with each participant individually to ensure the best care. In some cases, participants chose not to follow the protocol or preferred to work with their own medical practitioner for medication adjustment. See eTables 3 and 4 in [Supplement 2](#note-ZOI180057-1-s){ref-type="supplementary-material"} for detailed information.

Participants were asked to test and record their fasting blood glucose levels daily before breakfast, with 2 extra readings requested on intermittent energy restriction diet days, including a reading before bedtime. If the blood glucose level was less than 72 mg/dL (to convert to millimoles per liter, multiply by 0.0555), participants were asked to contact the study investigators. Medication changes were then made over the telephone or via email in consultation with the endocrinologist. The records of blood glucose levels were reviewed at each clinic visit, and if the levels were higher than 180 mg/dL, dietary compliance was checked and medication changes were made if necessary. Medication dosages were recorded daily, and the medication effect score (MES) was used to quantify changes. The MES is calculated as (actual drug dose/maximum drug dose) × drug mean adjustment factor.^[@zoi180057r15]^ A higher MES corresponded to a higher dose of diabetes medication, and a reduction in MES corresponded to a reduction in diabetes medication. For example, a 0.5-MES change in the dose of metformin hydrochloride equals a reduction by 1000 mg.

Outcome Measures {#H2-5-ZOI180057}
----------------

All outcome measures were taken at baseline, 3 months, and 12 months. The primary outcome was change in HbA~1c~ level measured using a DCA (Diabetes Care Analyzer) Vantage Analyzer (Siemens Healthcare Diagnostics) calibrated every 2 weeks. Disposable lancets were used to obtain the sample. The secondary outcome was change in body weight measured (barefoot while wearing light clothing) at each clinic visit on calibrated digital scales in the fasted state (minimum, 8 hours). Body composition was measured by dual-energy x-ray absorptiometry (Lunar iDXA, Getz Healthcare) by a licensed radiation technician. Exploratory outcomes included daily step count, which was monitored via a waistband pedometer (G-sensor, Pocket Pedometer, Walking With Attitude). Participants were encouraged to increase their step count by 2000 from baseline in line with the recommendation of small changes to achieve weight loss.^[@zoi180057r16]^ Participants attended each clinic visit at similar times after at least 1 habitual eating day to match the baseline. Blood samples were obtained to measure fasting glucose and lipid levels, frozen at --80°C, and analyzed at the end of the intervention using Konelab analysis (Konelab 20XTi, Thermo Electron Corporation) at the University of South Australia.

Statistical Analysis {#H2-6-ZOI180057}
--------------------

Sample size was calculated using the standard deviation of the change in HbA~1c~ level from our pilot data.^[@zoi180057r10]^ We required a minimum sample size of 104 participants to demonstrate equivalence between groups: *P* \< .05 with 80% power and a 90% CI boundary of ±0.5%. For weight, a very similar number was required, using a boundary limit of ±2.5 kg (±1.75 kg for fat mass and ±0.75 kg for fat-free mass). The predefined margin of equivalence for HbA~1c~ level, weight, fat mass, and fat-free mass was based on clinical relevance. A 0.5% change in HbA~1c~ level is considered to be a significant clinical change and is half the expected change achieved by most hypoglycemic drugs.^[@zoi180057r17]^ All other measures were exploratory, and we had no hypothesis with regard to equivalence, so only superiority tests were performed.

Analyses were performed using SPSS, version 21 (IBM SPSS Statistical Software), and data are shown as mean (standard error of the mean) values unless otherwise stated. A 2-tailed *P* \< .05 was considered statistically significant. Independent samples *t* tests and Pearson χ^2^ tests were used to analyze differences between groups at baseline. Change over time, differences between treatments, and time by treatment interactions were assessed on an intention-to-treat basis, including data from all 137 participants who underwent randomization under a missing-at-random assumption tested using a linear mixed model and from 97 completers using repeated-measures analysis of variance. Factors significant in a Pearson correlation were entered into stepwise linear regression to determine independent factors associated with major outcome measures at 12 months. Graphs were generated using Microsoft Excel 2010 for Windows (Microsoft Inc), and data were reported as the mean between-group difference in change, with a 2-sided 90% confidence interval, including the equivalence margin. The full statistical analysis plan is available in [Supplement 1](#note-ZOI180057-1-s){ref-type="supplementary-material"}.

Results {#H1-3-ZOI180057}
=======

Of the 195 participants screened, 137 Australian adults with type 2 diabetes (77 women and 60 men; mean \[SD\] age, 61.0 \[9.1\] years; mean \[SD\] body mass index, 36.0 \[5.8\]; and mean \[SD\] HbA~1c~ level, 7.3% \[1.3%\]) were randomly assigned to diet groups. Of these 137 participants, 67 were randomized to the continuous energy restriction group and 70 were randomized to the intermittent energy restriction group. Ninety-seven participants (70.8%) completed the study ([Figure 1](#zoi180057f1){ref-type="fig"}), and the dropout rates were similar in both groups (21 participants \[31.3%\] in the continuous energy restriction group and 19 participants \[27.1%\] in the intermittent energy restriction group; *P* = .71). Baseline characteristics were comparable between groups ([Table 1](#zoi180057t1){ref-type="table"}).
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###### Baseline Characteristics of Participants[^a^](#zoi180057t1n1){ref-type="table-fn"}

  Characteristic                                                      Mean (SD) Value                                             
  ------------------------------------------------------------------- ----------------- ------------- ------------- ------------- -------------
  Age, y                                                              61.0 (9.2)        61.0 (9.0)    61.0 (9.1)    62.0 (8.8)    59.0 (9.6)
  Sex, No. (%)                                                                                                                    
  Female                                                              38 (56.7)         39 (55.7)     77 (56.2)     48 (49.5)     29 (72.5)
  Male                                                                29 (43.3)         31 (44.3)     60 (43.8)     49 (50.5)     11 (27.5)
  Duration of diabetes, y                                             8.1 (6.5)         7.9 (5.9)     8.0 (6.2)     7.9 (6.2)     8.3 (6.2)
  Glycemic control                                                                                                                
  HbA~1c~, %                                                          7.5 (1.4)         7.2 (1.2)     7.3 (1.3)     7.1 (1.2)     7.8 (1.4)
  FPG, mg/dL                                                          158 (44)          149 (39)      153 (42)      154 (42)      148 (42)
  Diabetes medications, No. (%)                                                                                                   
  Diet                                                                20 (29.9)         18 (25.7)     38 (27.7)     27 (27.8)     11 (27.5)
  OHA                                                                 39 (58.2)         43 (61.4)     82 (59.9)     57 (58.8)     25 (62.5)
  Metformin                                                           43 (64.2)         46 (65.7)     89 (65.0)     65 (67.0)     24 (60.0)
  DPP-4 inhibitors                                                    11 (16.4)         9 (12.9)      20 (14.6)     13 (13.4)     7 (17.5)
  SGLT2 inhibitors                                                    4 (6.0)           4 (5.7)       8 (5.8)       3 (3.1)       5 (12.5)
  GLP-1 agonists                                                      4 (6.0)           1 (1.4)       5 (3.6)       4 (4.1)       1 (2.5)
  Sulfonylureas                                                       12 (17.9)         18 (25.7)     30 (21.9)     21 (21.6)     9 (22.5)
  Insulin                                                             14 (20.9)         14 (20.0)     28 (20.4)     21 (21.6)     7 (17.5)
  Medication effect score[^b^](#zoi180057t1n2){ref-type="table-fn"}                                                               
  OHA                                                                 1.4 (0.8)         1.3 (0.8)     1.4 (0.8)     1.3 (0.8)     1.4 (0.7)
  Insulin                                                             1.5 (1.1)         1.8 (1.1)     1.6 (1.1)     1.5 (0.9)     2.1 (1.6)
  Total                                                               1.8 (1.1)         1.7 (1.3)     1.8 (1.2)     1.7 (1.2)     1.8 (1.1)
  CVD risk markers                                                                                                                
  Lipid-lowering, No. (%)                                             41 (61.2)         46 (65.7)     87 (63.5)     64 (66.0)     23 (57.5)
  Total cholesterol, mg/dL                                            195 (64)          179 (48)      186 (56)      187 (60)      181 (23)
  HDL cholesterol, mg/dL                                              46 (17)           47 (14)       47 (16)       46 (16)       50 (13)
  LDL cholesterol, mg/dL                                              116 (50)          107 (43)      111 (46)      111 (49)      108 (24)
  Triglycerides, mg/dL                                                168 (127)         129 (62)      147 (99)      151 (104)     116 (40)
  Body weight and composition                                                                                                     
  Weight, kg                                                          102 (17)          100 (19)      101 (18)      100 (17)      103 (19)
  BMI                                                                 37 (5.7)          35 (5.8)      36 (5.8)      35 (5.6)      37 (6.1)
  Total body fat, %                                                   44 (6.6)          42 (7.3)      43 (7.0)      42 (7.1)      45 (6.2)
  Total fat mass, kg                                                  42 (9.1)          40 (9.4)      41 (9.3)      40 (9.2)      43 (9.4)
  Total fat-free mass, kg                                             54 (9.5)          54 (9.8)      54 (9.6)      55 (9.6)      52 (9.5)
  Android fat, %[^c^](#zoi180057t1n3){ref-type="table-fn"}            52 (5.6)          51 (6.1)      52 (5.9)      51 (6.1)      53 (5.1)
  Android fat mass, kg                                                4.8 (1.2)         4.4 (1.1)     4.6 (1.2)     4.5 (1.1)     4.8 (1.3)
  Android fat-free mass, kg                                           4.3 (0.9)         4.2 (0.8)     4.2 (0.8)     4.2 (0.8)     4.3 (1.0)
  VAT, kg                                                             2.5 (0.9)         2.2 (0.9)     2.3 (0.9)     2.4 (0.9)     2.4 (0.9)
  Physical activity                                                                                                               
  Activity count, steps/d                                             5889 (2893)       6800 (3187)   6363 (3071)   6327 (3088)   7180 (2206)

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase 4; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide 1 receptor; HbA~1c~, hemoglobin A~1c~; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OHA, oral hypoglycemic agents; SGLT2, sodium-glucose cotransporter 2; VAT, visceral adipose tissue.

SI conversion factors: To convert HbA~1c~ to proportion of total hemoglobin, multiply by 0.01; FPG to millimoles per liter, multiply by 0.0555; total, HDL, and LDL cholesterol to millimoles per liter, multiply by 0.0259; and triglycerides to millimoles per liter, multiply by 0.0113.

Data were analyzed using independent samples *t* test (for continuous variables) and χ^2^ test (for categorical variables) and given as mean (SD) value.

Medication effect score: (actual drug dose/maximum drug dose) × drug mean adjustment factor.

Percentage fat of tissue in the android region.

From baseline to 12 months, the mean (SEM) HbA~1c~ level was reduced significantly, with no difference between treatment groups (--0.5% \[0.2%\] in the continuous energy restriction group vs --0.3% \[0.1%\] in the intermittent energy restriction group; *P* = .65), and the results did not differ using completers analysis (eTable 5 in [Supplement 2](#note-ZOI180057-1-s){ref-type="supplementary-material"}). For the primary outcome, the mean between-group difference in the change in HbA~1c~ level was 0.2% (90% CI, --0.2% to 0.5%) and was contained within the equivalence margin of ±0.5%, confirming equivalence ([Figure 2](#zoi180057f2){ref-type="fig"}). There was an increase in the mean (SEM) HbA~1c~ level in both groups between 3 and 12 months (0.3% \[0.1%\]), with an overall decrease of 0.4% (0.1%) (*P* \< .001) at 12 months. In stepwise linear regression, the baseline HbA~1c~ level accounted for 35% and the change in visceral adipose tissue accounted for 17% of the variance in the change in HbA~1c~ level at 12 months (adjusted *r*^2^ = 0.5; *P* \< .001), with no effect of treatment group. Participants with a baseline HbA~1c~ level higher than 8% had the greatest mean (SEM) change (--1.4% \[0.2%\]; *P* \< .001), and participants with a baseline HbA~1c~ level of less than 6% had almost no change (--0.03% \[0.05%\]; *P* = .50) at 12 months.

![Mean Between-Group Difference in Change in Hemoglobin A~1c~ Level, Weight, and Body Composition for the Intermittent vs Continuous Groups (Intention-to-Treat Analysis)\
To convert hemoglobin A~1c~ to proportion of total hemoglobin, multiply by 0.01. Error bars indicate 2-sided 90% confidence intervals. Tinted area indicates zone of equivalence.](jamanetwopen-1-e180756-g002){#zoi180057f2}

The total mean (SEM) MES decreased significantly by time (--0.5 \[0.1\]; *P* \< .001), was similar in both groups (--0.3 \[0.1\] in the continuous energy restriction group vs --0.6 \[0.1\] in the intermittent energy restriction group; *P* = .11), and was correlated with weight change at 12 months (*r* = 0.3; *P* = .009). The mean (SEM) MES for oral hypoglycemic agents decreased significantly by time (--0.3 \[0.1\]; *P* \< .001) and was similar in both groups (--0.2 \[0.1\] in the continuous energy restriction group vs --0.3 \[0.1\] in the intermittent energy restriction group; *P* = .45), but, for insulin, the decrease was significantly greater in the intermittent energy restriction group owing to the extra insulin reduction required on intermittent diet days (--0.3 \[0.1\] in the continuous energy restriction group vs --1.2 \[0.2\] in the intermittent energy restriction group; *P* = .006). Most of the changes to medications were made before 3 months, with small changes between 3 and 12 months (total mean \[SEM\] MES, --0.1 \[0.05\]; *P* = .02), with no difference between groups (with a total mean \[SEM\] MES of --0.06 \[0.05\] in the continuous energy restriction group vs --0.2 \[0.08\] in the intermittent energy restriction group; *P* = .28). Thirty-five percent of participants (16 of 46) using sulfonylureas and/or insulin experienced glycemic events (the mean \[SEM\] number of events was 3.2 \[0.7\] in the continuous energy restriction group and 4.9 \[1.4\] in the intermittent energy restriction group; *P* = .28) in the first 2 weeks of treatment. Eight of 46 participants (17%) (2 in the continuous energy restriction group and 6 in the intermittent energy restriction group) experienced hypoglycemia (mean \[SEM\] number of events, 2.4 \[0.6\]) with no differences between groups (the mean \[SEM\] number of events was 2.0 \[1.0\] in the continuous energy restriction group vs 2.5 \[0.8\] in the intermittent energy restriction group; *P* = .74). All participants who experienced hypoglycemic events either reported events before starting treatment or were unsure. One participant in the intermittent energy restriction group who experienced hypoglycemia during the first 2 weeks of treatment did not lose weight during this time. Hyperglycemia occurred in 10 of 46 participants (22%; 3 in the continuous energy restriction group and 7 in the intermittent energy restriction group) in the first 2 weeks (mean \[SEM\] number of events, 5.1 \[1.4\]), with no difference between groups (the mean \[SEM\] number of events was 4.0 \[0.6\] in the continuous energy restriction group vs 5.6 \[2.0\] in the intermittent energy restriction group; *P* = .47). Three participants did not lose weight during this period (1 in the continuous energy restriction group and 2 in the intermittent energy restriction group). Four participants chose not to follow the protocol or chose to follow their own medical practitioner's advice (eTables 3 and 4 in [Supplement 2](#note-ZOI180057-1-s){ref-type="supplementary-material"}).

The analysis of the secondary outcome showed that the mean \[SEM\] weight reduction was significant over time but not by treatment (--5.0 \[0.8\] kg in the continuous energy restriction group vs --6.8 \[0.8\] kg in the intermittent energy restriction group; *P* = .25), and the results did not differ using completer analysis (eTable 5 in [Supplement](#note-ZOI180057-1-s){ref-type="supplementary-material"}). The mean between-group difference in weight change was --1.8 kg (90% CI, --3.7 to 0.07 kg), which is outside the prespecified boundary of ±2.5 kg, so statistical equivalence has not been shown ([Figure 2](#zoi180057f2){ref-type="fig"}). Twenty percent of participants (19 of 97) lost 5% to 10% of their body weight, and 22% (21 of 97) lost more than 10% of their body weight, with no difference between groups. Both groups lost significant weight between baseline and 3 months, which was maintained at 12 months (mean \[SEM\] weight reduction from 3 to 12 months was 0.4 \[0.5\] kg in the continuous energy restriction group and --0.2 \[0.6\] kg in the intermittent energy restriction group; *P* = .48). Weight change at 2 weeks was associated with weight loss at 12 months (*r* = 0.6; *P* \< .001). A small subgroup of participants (21 in both groups) continued to lose weight during the 12 months of the study (mean \[SEM\] weight reduction was --8.4 \[1.2\] kg in the continuous energy restriction group and --12.5 \[1.8\] kg in the intermittent energy restriction group; *P* = .07), and these participants maintained the lower HbA~1c~ level seen at 3 to 12 months (mean \[SEM\] level, 0.6% \[0.2%\]; *P* \< .001) with no difference by treatment. Participants who attended all scheduled visits lost significantly more weight than did participants who did not (mean \[SEM\], --7.6 \[0.9\] kg vs --4.0 \[1.1\] kg; *P* = .01), with a trend toward a greater change in HbA~1c~ level (mean \[SEM\] level, --0.5% \[0.1%\] vs --0.2% \[0.1%\]; *P* = .09). In stepwise linear regression, change in step count at 3 months accounted for 9%, and the baseline step count accounted for 5% of the change in weight at 12 months (adjusted *r*^2^ = 0.1; *P* \< .001), with no effect of treatment group. All measures of body composition decreased significantly over time, with no difference between groups ([Table 2](#zoi180057t2){ref-type="table"}). The mean between-group differences in change were --1.3 kg (90% CI, --2.8 to 0.2 kg) for fat mass and --0.5 kg (90% CI, --1.4 to 0.4 kg) for fat-free mass, which are outside the prespecified boundaries of ±1.75 kg for fat mass and ±0.75 kg for fat-free mass, so statistical equivalence has not been shown ([Figure 2](#zoi180057f2){ref-type="fig"}). The total loss of fat-free mass was significantly greater in the intermittent energy restriction group using completers analysis (eTable 5 in [Supplement 2](#note-ZOI180057-1-s){ref-type="supplementary-material"}) but did not differ between groups when expressed as a mean (SEM) percentage of weight lost (31% \[8.5%\] in the continuous energy restriction group and 37% \[9.6%\] in the intermittent energy restriction group; *P* = .61).

###### Primary, Secondary, and Exploratory Outcomes From Baseline to 12 Months for Intermittent vs Continuous Groups (Intention-to-Treat Analysis)[^a^](#zoi180057t2n1){ref-type="table-fn"}

  Variable                                                                                                Mean (SEM) \[95% CI\]          *P* Value for Time   Mean (SEM) \[95% CI\]           *P* Value for Diet by Time      
  ------------------------------------------------------------------------------------------------------- ------------------------------ -------------------- ------------------------------- ------------------------------- -----
  Primary outcome                                                                                                                                                                                                             
  HbA~1c~, %                                                                                              −0.4 (0.1) \[−0.6 to −0.2\]    \<.001               −0.5 (0.2) \[−0.8 to −0.2\]     −0.3 (0.1) \[−0.6 to −0.08\]    .65
  Secondary outcomes                                                                                                                                                                                                          
  Weight, kg                                                                                              −5.9 (0.6) \[−7.1 to −4.8\]    \<.001               −5.0 (0.8) \[−6.6 to −3.5\]     −6.8 (0.8) \[−8.5 to −5.1\]     .25
  BMI                                                                                                     −2.1 (0.2) \[−2.5 to −1.7\]    \<.001               −1.9 (0.3) \[−2.4 to −1.3\]     −2.3 (0.3) \[−2.9 to −1.7\]     .43
  Total body fat, %[^b^](#zoi180057t2n2){ref-type="table-fn"}                                             −1.8 (0.4) \[−2.5 to −1.1\]    \<.001               −1.6 (0.3) \[−2.2 to −0.9\]     −2.3 (0.6) \[−3.5 to −1.1\]     .20
  Total fat mass, kg[^b^](#zoi180057t2n2){ref-type="table-fn"}                                            −4.1 (0.5) \[−5.0 to −3.2\]    \<.001               −3.4 (0.6) \[−4.6 to −2.2\]     −4.7 (0.7) \[−6.1 to −3.4\]     .20
  Total fat-free mass, kg[^b^](#zoi180057t2n2){ref-type="table-fn"}                                       −1.8 (0.3) \[−2.4 to −1.3\]    \<.001               −1.6 (0.4) \[−2.3 to −0.8\]     −2.1 (0.4) \[−2.9 to −1.4\]     .11
  Android fat, %[^b^](#zoi180057t2n2){ref-type="table-fn"}^,^[^c^](#zoi180057t2n3){ref-type="table-fn"}   −3.8 (1.1) \[−5.9 to −1.7\]    \<.001               −2.0 (1.2) \[−4.4 to −0.5\]     −5.6 (1.7) \[−9.0 to −2.1\]     .23
  Android fat mass, kg[^b^](#zoi180057t2n2){ref-type="table-fn"}                                          −0.8 (0.2) \[−1.2 to −0.5\]    \<.001               −0.6 (0.2) \[−1.1 to −0.2\]     −1.1 (0.2) \[−1.5 to −0.6\]     .37
  Android fat-free mass, kg[^b^](#zoi180057t2n2){ref-type="table-fn"}                                     −0.3 (0.1) \[−0.5 to −0.04\]   .05                  −0.3 (0.2) \[−0.6 to −0.02\]    −0.3 (0.2) \[−0.6 to −0.08\]    .75
  VAT, kg[^b^](#zoi180057t2n2){ref-type="table-fn"}                                                       −0.2 (0.06) \[−0.3 to −0.1\]   \<.001               −0.2 (0.09) \[−0.4 to −0.02\]   −0.2 (0.09) \[−0.4 to −0.08\]   .42

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HbA~1c~, hemoglobin A~1c~; VAT, visceral adipose tissue.

SI conversion factor: To convert HbA~1c~ to proportion of total hemoglobin, multiply by 0.01.

Data were included for 137 participants (67 in the continuous energy restriction group and 70 in the intermittent energy restriction group) unless otherwise stated: mean (SEM) and 95% CI were estimated using an intention-to-treat analysis with a linear mixed model.

For a total of 128 participants (64 in the continuous energy restriction group and 64 in the intermittent energy restriction group) with weight greater than 130 kg or who declined dual-energy x-ray absorptiometry scan.

Percentage fat of tissue in the android region.

The exploratory outcomes of mean (SEM) fasting glucose (--18.1 \[4.6\] mg/dL) and serum lipid levels (total cholesterol level, --13.0 \[3.9\] mg/dL \[to convert to millimoles per liter, multiply by 0.0259\]; low-density lipoprotein cholesterol level, --11.1 \[3.3\] mg/dL \[to convert to millimoles per liter, multiply by 0.0259\]; triglycerides level, --16.0 \[8.5\] mg/dL \[to convert to millimoles per liter, multiply by 0.0113\]; and high-density lipoprotein cholesterol level, --1.4 \[1.5\] mg/dL \[to convert to millimoles per liter, multiply by 0.0259\]) improved with weight loss (*P* \< .001), with no differences between groups. The increase in mean (SEM) steps per day was significantly greater in the continuous energy restriction group than the intermittent energy restriction group at 12 months (1183 \[516\] steps vs 524 \[483\] steps; *P* = .02), but the total step count was still similar in both groups (7071 \[529\] steps in the continuous energy restriction group vs 7312 \[496\] steps in the intermittent energy restriction group; *P* = .52). Effects did not differ using completers analysis.

Discussion {#H1-4-ZOI180057}
==========

To our knowledge, this is the first randomized clinical trial of this duration comparing intermittent energy restriction with continuous energy restriction in patients with type 2 diabetes. The results demonstrated that a 2-day intermittent energy restriction diet is comparable to a continuous energy restriction diet for improvements in glycemic control, confirming our pilot data.^[@zoi180057r10]^ Equivalence was demonstrated for change in HbA~1c~ level; however, given the large variability in weight reduction, equivalence could not be demonstrated for weight loss or changes in body composition. Intermittent energy restriction may be superior to continuous energy restriction for weight reduction, although a sample population of more than 300 participants would be required to demonstrate superiority with 80% power.

The major factor associated with change in HbA~1c~ level was baseline HbA~1c~ level, and because participants had relatively well-controlled type 2 diabetes, our capacity to see a large change was limited. It has been well demonstrated that the magnitude of the effect of an intervention on glycemic control depends on baseline HbA~1c~ level.^[@zoi180057r18]^ The change in HbA~1c~ level in our trial is comparable to the change seen in trials with similar baseline HbA~1c~ level, such as the Look AHEAD (Action for Health in Diabetes) study.^[@zoi180057r19]^ Long duration of diabetes was associated with a higher baseline HbA~1c~ level, which resulted in a greater reduction in HbA~1c~ level. Relative weight maintenance from 3 to 12 months probably contributed to the loss of effect on HbA~1c~ level during this period because participants who continued to lose weight maintained improved HbA~1c~ levels. The slight but nonsignificant difference in change in HbA~1c~ level between groups may be because the 5 days of nonrestricted habitual eating for those in the intermittent energy restriction group had no specific emphasis on improved dietary choices as were provided to those in the continuous energy restriction group.

Intermittent energy restriction is safe for people who have either diet-controlled type 2 diabetes or are using medication that is not likely to cause hypoglycemia. For people using sulfonylureas and/or insulin, intermittent energy restriction requires medication changes and regular monitoring, especially in the initial stages. Patients need to be able to contact their medical practitioner for further medication changes if they experience a hypoglycemic event. In our trial, hypoglycemic events occurred only in participants who reported experiencing hypoglycemia before starting treatment or who were uncertain.

In this pragmatic trial, every effort was made to try and replicate the real-world environment; therefore, no meal replacements or foods were provided. Considering this fact, acceptability of the energy restriction plans was very high, with only 2 participants from the intermittent energy restriction group withdrawing owing to headaches brought on by hunger. Overall compliance to both diets was excellent during the first 3 months of treatment (90% in the continuous energy restriction group and 97% in the intermittent energy restriction group; *P* = .21), after which the compliance rates decreased in both groups (49% in the continuous energy restriction group and 44% in the intermittent energy restriction group; *P* = .62). Anecdotally, participants in the intermittent energy restriction group reported that although they were not following the protocol consistently after 3 months, they found that they could use it effectively to prevent weight gain because the energy restriction involved only 2 days. Intermittent dieting has been shown to improve the efficiency of weight loss compared with continuous dieting,^[@zoi180057r20]^ although we did not find this result in the present study. The continuous energy restriction group found weight loss maintenance more difficult because, if they were not following the diet on a daily basis, they would regain weight owing to increased energy intake. Weight loss was greater in a subgroup of participants who attended all scheduled clinic visits with the study dietitian compared with participants who missed sessions. The benefits of behavioral support,^[@zoi180057r21]^ specifically support provided by a dietitian,^[@zoi180057r22]^ as well as the effects of lifestyle interventions,^[@zoi180057r23]^ are noted in the literature. There was a significant difference in loss of total fat-free mass, which was greater in the intermittent energy restriction group for completers. This difference did not occur in our pilot trial, nor is it seen in the literature on intermittent energy restriction in overweight and obese individuals.^[@zoi180057r5],[@zoi180057r10]^ We do not believe that this finding is clinically relevant, considering the greater weight loss in the intermittent energy restriction group at 12 months (approximately 2 kg) and because the total fat-free mass percentage change did not differ between groups.

Limitations {#H2-7-ZOI180057}
-----------

This study has some limitations. First, as indicated, this population had well-controlled type 2 diabetes, which limits generalizability. Second, we acknowledge that medication adjustments can cause problems with interpreting changes in HbA~1c~ level. Changes to medications were similar between groups, except for reductions in insulin, which were greater in the intermittent energy restriction group and may have limited changes in HbA~1c~ level. Third, participants had more contact time with the dietitian than is usual in the clinical setting, especially in the first 3 months, which may have affected the results. Finally, only finger-prick testing was used to monitor blood glucose levels, and it is likely that hyperglycemic and hypoglycemic events went undetected.^[@zoi180057r24]^ Future research should use continuous blood glucose monitoring systems for more accurate results.

Conclusions {#H1-5-ZOI180057}
===========

Intermittent energy restriction is an effective alternative diet strategy for the reduction of HbA~1c~ level comparable to continuous energy restriction in patients with type 2 diabetes, and it may be superior to continuous energy restriction for weight reduction. Intermittent energy restriction is acceptable for most patients with type 2 diabetes, and safety can be ensured for patients who are not using glycemic agents likely to cause hypoglycemia. For patients using sulfonylureas and/or insulin, regular monitoring is paramount. The relative maintenance of results between the 3- and 12-month periods may reflect the importance of support for behavioral change, which was provided more frequently in the first 3 months of treatment and resulted in greater change if participants attended all appointments.
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